



## DRUG INTERACTIONS WITH TOBACCO SMOKE

Many interactions between tobacco smoke and medications have been identified. Note that in most cases it is the tobacco smoke—not the nicotine—that causes these drug interactions. Tobacco smoke interacts with medications through pharmacokinetic (PK) and pharmacodynamic (PD) mechanisms. PK interactions affect the absorption, distribution, metabolism, or elimination of other drugs, potentially causing an altered pharmacologic response. The majority of PK interactions with smoking are the result of induction of hepatic cytochrome P450 enzymes (primarily CYP1A2). Smokers may require higher doses of medications that are CYP1A2 substrates. Upon cessation, dose reductions might be needed. PD interactions alter the expected response or actions of other drugs. The amount of tobacco smoking needed to have an effect has not been established, and the assumption is that any smoker is susceptible to the same degree of interaction.

**The most clinically significant interactions are depicted in the shaded rows.**

DRUG/CLASS	MECHANISM OF INTERACTION AND EFFECTS
<b>Pharmacokinetic Interactions</b>	
Alprazolam (Xanax®)	<ul style="list-style-type: none"> <li>Conflicting data on significance, but possible ↓ plasma concentrations (up to 50%); ↓ half-life (35%).</li> </ul>
Bendamustine (Treanda®)	<ul style="list-style-type: none"> <li>Metabolized by CYP1A2. Manufacturer recommends using with caution in smokers due to likely ↓ bendamustine concentrations, with ↑ concentrations of its two active metabolites.</li> </ul>
Caffeine	<ul style="list-style-type: none"> <li>↑ Metabolism (induction of CYP1A2); ↑ clearance (56%). Caffeine levels likely ↑ after cessation.</li> </ul>
Chlorpromazine (Thorazine®)	<ul style="list-style-type: none"> <li>↓ Area under the curve (AUC) (by 36%) and serum concentrations (by 24%).</li> <li>↓ Sedation and hypotension possible in smokers; smokers may require ↑ dosages.</li> </ul>
Clopidogrel (Plavix®)	<ul style="list-style-type: none"> <li>↑ Metabolism (induction of CYP1A2) of clopidogrel to its active metabolite.</li> <li>Clopidogrel's effects are enhanced in smokers (≥10 cigarettes/day): significant ↑ platelet inhibition, ↓ platelet aggregation; while improved clinical outcomes have been shown, may also ↑ risk of bleeding.</li> </ul>
Clozapine (Clozaril®)	<ul style="list-style-type: none"> <li>↑ Metabolism (induction of CYP1A2); ↓ plasma concentrations (by 18%).</li> <li>↑ Levels upon cessation may occur; closely monitor drug levels and reduce dose as required to avoid toxicity.</li> </ul>
Erlotinib (Tarceva®)	<ul style="list-style-type: none"> <li>↑ Clearance (24%); ↓ trough serum concentrations (2-fold).</li> </ul>
Flecainide (Tambocor®)	<ul style="list-style-type: none"> <li>↑ Clearance (61%); ↓ trough serum concentrations (by 25%). Smokers may need ↑ dosages.</li> </ul>
Fluvoxamine (Luvox®)	<ul style="list-style-type: none"> <li>↑ Metabolism (induction of CYP1A2); ↑ clearance (24%); ↓ AUC (31%); ↓ Cmax (by 32%) and C<sub>ss</sub> (by 39%).</li> <li>Dosage modifications not routinely recommended but smokers may need ↑ dosages.</li> </ul>
Haloperidol (Haldol®)	<ul style="list-style-type: none"> <li>↑ Clearance (44%); ↓ serum concentrations (70%); data are inconsistent therefore clinical significance is unclear.</li> </ul>
Heparin	<ul style="list-style-type: none"> <li>Mechanism unknown but ↑ clearance and ↓ half-life are observed. Smoking has prothrombotic effects.</li> <li>Smokers may need ↑ dosages due to PK and PD interactions.</li> </ul>
Insulin, subcutaneous	<ul style="list-style-type: none"> <li>Possible ↓ insulin absorption secondary to peripheral vasoconstriction.</li> <li>Smoking may cause release of endogenous substances that cause insulin resistance.</li> <li>PK &amp; PD interactions likely not clinically significant, but smokers may need ↑ dosages.</li> </ul>
Irinotecan (Camptosar®)	<ul style="list-style-type: none"> <li>↑ Clearance (18%); ↓ serum concentrations of active metabolite, SN-38 (~40%; via induction of glucuronidation); ↓ systemic exposure resulting in lower hematologic toxicity and may reduce efficacy.</li> <li>Smokers may need ↑ dosages.</li> </ul>
Methadone	<ul style="list-style-type: none"> <li>Possible ↑ metabolism (induction of CYP1A2, a minor pathway for methadone).</li> <li>Carefully monitor response upon cessation.</li> </ul>
Mexiletine (Mexitol®)	<ul style="list-style-type: none"> <li>↑ Clearance (25%; via oxidation and glucuronidation); ↓ half-life (36%).</li> </ul>
Olanzapine (Zyprexa®)	<ul style="list-style-type: none"> <li>↑ Metabolism (induction of CYP1A2); ↑ clearance (98%); ↓ serum concentrations (by 12%).</li> <li>Dosage modifications not routinely recommended but smokers may need ↑ dosages.</li> </ul>

<b>Pharmacokinetic Interactions (continued)</b>	
<b>DRUG/CLASS</b>	<b>MECHANISM OF INTERACTION AND EFFECTS</b>
Propranolol (Inderal®)	<ul style="list-style-type: none"> <li>▪ ↑ Clearance (77%; via side-chain oxidation and glucuronidation).</li> </ul>
Riociguat (Adempas®)	<ul style="list-style-type: none"> <li>▪ ↓ Plasma concentrations (by 50–60%).</li> <li>▪ Smokers may require dosages higher than 2.5 mg three times a day; consider dose reduction upon cessation.</li> </ul>
Ropinirole (Requip®)	<ul style="list-style-type: none"> <li>▪ ↓ C<sub>max</sub> (by 30%) and AUC (by 38%) in study with patients with restless legs syndrome.</li> <li>▪ Smokers may need ↑ dosages.</li> </ul>
Tacrine (Cognex®)	<ul style="list-style-type: none"> <li>▪ ↑ Metabolism (induction of CYP1A2); ↓ half-life (50%); serum concentrations 3-fold lower.</li> <li>▪ Smokers may need ↑ dosages.</li> </ul>
Tasimelteon (Hetlioz®)	<ul style="list-style-type: none"> <li>▪ ↑ Metabolism (induction of CYP1A2); drug exposure ↓ by 40%.</li> <li>▪ Smokers may need ↑ dosages.</li> </ul>
Theophylline (Theo-Dur®, etc.)	<ul style="list-style-type: none"> <li>▪ ↑ Metabolism (induction of CYP1A2); ↑ clearance (58–100%); ↓ half-life (63%).</li> <li>▪ Levels should be monitored if smoking is initiated, discontinued, or changed. Maintenance doses are considerably higher in smokers; ↑ clearance also with second-hand smoke exposure.</li> </ul>
Tizanidine (Zanaflex®)	<ul style="list-style-type: none"> <li>▪ ↓ AUC (30–40%) and ↓ half-life (10%) observed in male smokers.</li> </ul>
Tricyclic antidepressants (e.g., imipramine, nortriptyline)	<ul style="list-style-type: none"> <li>▪ Possible interaction with tricyclic antidepressants in the direction of ↓ blood levels, but the clinical significance is not established.</li> </ul>
Warfarin	<ul style="list-style-type: none"> <li>▪ ↑ Metabolism (induction of CYP1A2) of R-enantiomer; however, S-enantiomer is more potent and effect on INR is inconclusive. Consider monitoring INR upon smoking cessation.</li> </ul>
<b>Pharmacodynamic Interactions</b>	
Benzodiazepines (diazepam, chlordiazepoxide)	<ul style="list-style-type: none"> <li>▪ ↓ Sedation and drowsiness, possibly caused by nicotine stimulation of central nervous system.</li> </ul>
Beta-blockers	<ul style="list-style-type: none"> <li>▪ Less effective BP and heart rate control effects; possibly caused by nicotine-mediated sympathetic activation.</li> <li>▪ Smokers may need ↑ dosages.</li> </ul>
Corticosteroids, inhaled	<ul style="list-style-type: none"> <li>▪ Smokers with asthma may have less of a response to inhaled corticosteroids.</li> </ul>
Hormonal contraceptives (combined)	<ul style="list-style-type: none"> <li>▪ ↑ Risk of cardiovascular adverse effects (e.g., stroke, myocardial infarction, thromboembolism) in women who smoke and use combined hormonal contraceptives. Ortho Evra patch users shown to have 2-fold ↑ risk of venous thromboembolism compared with oral contraceptive users, likely due to ↑ estrogen exposure (60% higher levels).</li> <li>▪ ↑ Risk with age and with heavy smoking (≥15 cigarettes per day) and is quite marked in women ≥35 years old.</li> </ul>
Serotonin 5-HT <sub>1</sub> receptor agonists (triptans)	<ul style="list-style-type: none"> <li>▪ This class of drugs may cause coronary vasospasm; caution for use in smokers due to possible unrecognized CAD.</li> </ul>
Adapted and updated, from Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update. <i>Clin Pharmacokinet</i> 1999;36:425–38 and Kroon LA. Drug interactions with smoking. <i>Am J Health-Syst Pharm</i> 2007;64:1917-21.	